Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19
Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19
Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
Gilead Sciences Announces First Quarter 2024 Financial Results
My month of vermouth-rinsing and fat-washing.
Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
Learn more about our partnerships with community organizations to help address health challenges and barriers to care around the world.
FDA Expands Indication for Gilead’s Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Gilead Sciences Announces Completion of Acquisition of CymaBay